생물정신의학 (Korean Journal of Biological Psychiatry)

  • 제24권3호
  • /
  • Pages.162-166
  • /
  • 2017
  • /
  • 1225-8709(pISSN)
  • /
  • 2005-7571(eISSN)
대한생물정신의학회 (The Korean Society of Biological Psychiatry)
권호 표지

양극성장애에 대한 Valproic Acid와 Olanzapine 치료 중 발생한 호산구증가증과 전신증상을 동반한 약물발진(DRESS) 증후군 1예

A Case of Drug Rash with Eosinophilia and Systemic Symptoms Associated with Valproic Acid and Olanzapine Treatment in Patient with Bipolar Disorder

  • 이웅 (성균관대학교 의과대학 강북삼성병원 정신건강의학교실) ;
  • 임세원 (성균관대학교 의과대학 강북삼성병원 정신건강의학교실)
  • Lee, Ung (Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Lim, Se-Won (Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 투고 : 2017.04.21
  • 심사 : 2017.06.21
  • 발행 : 2017.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening, medication-induced hypersensitivity reaction with long latency. It is characterized by fever, rash, leukocytosis with eosinophilia, atypical lymphocytosis, and internal organ involvement. The most common causes of DRESS syndrome are sulfonamides and anticonvulsants such as carbamazepine and lamotrigine. However, valproic acid and olanzapine could develop DRESS syndrome. We report a case of DRESS syndrome associated with valproic acid and olanzapine in a 41 years old male patient with bipolar disorder.

키워드

참고문헌

  1. Coope R, Burrows RR. Treatment of epilepsy with sodium diphenyl hydantoinate. The Lancet 1940;235:490-492. https://doi.org/10.1016/S0140-6736(00)61376-4
  2. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006;55:1-8. https://doi.org/10.2332/allergolint.55.1
  3. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-257. https://doi.org/10.1016/S1085-5629(96)80038-1
  4. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. clinical perspectives. J Am Acad Dermatol 2013;68:693.e1-14; quiz 706-708. https://doi.org/10.1016/j.jaad.2013.01.033
  5. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-1080. https://doi.org/10.1111/bjd.12501
  6. FDA. fda.gov [homepage on the Internet]. FDA Drug Safety Communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax) [update 2015 May 10; cited 2017 Feb 24]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm499441.htm.
  7. Kim YH, Choi CW, Lee GY, Kim WS. A Case of Valproic Acid Induced DRESS Syndrome. Korean J Dermatol 2012;50:85-88.
  8. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285. https://doi.org/10.1056/NEJM199411103311906
  9. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-2536. https://doi.org/10.1002/art.34488
  10. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011;36:6-11. https://doi.org/10.1111/j.1365-2230.2010.03967.x
  11. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588- 597. https://doi.org/10.1016/j.amjmed.2011.01.017
  12. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010;146:1373-1379. https://doi.org/10.1001/archdermatol.2010.198
  13. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102: 4134-4139. https://doi.org/10.1073/pnas.0409500102
  14. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and metaanalysis. Pharmacogenomics J 2014;14:281-288. https://doi.org/10.1038/tpj.2013.40
  15. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf 2009;32:391-408. https://doi.org/10.2165/00002018-200932050-00003
  16. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-304.
  17. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-611. https://doi.org/10.1111/j.1365-2133.2006.07704.x
  18. Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol 2015;72:246-252. https://doi.org/10.1016/j.jaad.2014.10.032
  19. Roujeau JC. Treatment of severe drug eruptions. J Dermatol 1999; 26:718-722. https://doi.org/10.1111/j.1346-8138.1999.tb02082.x
  20. Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013; 68:459-465. https://doi.org/10.1016/j.jaad.2012.08.009